Exegenesis Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 65

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 11

Exegenesis General Information

Description

Developer of genetic medicines and oligo-based modalities intended for targeted delivery. The company mainly focuses on the research and development of gene therapy drugs and provides a unique gene therapy platform for a variety of major genetic diseases, enabling clients to receive effective treatment for genetic diseases.

Contact Information

Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • Rooms 301, 302, 401, and 402, Building 11
  • Hexiang Technology Center, Qiantang New District
  • Hangzhou, Zhejiang
  • China
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • Rooms 301, 302, 401, and 402, Building 11
  • Hexiang Technology Center, Qiantang New District
  • Hangzhou, Zhejiang
  • China

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exegenesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. IPO 20-Jan-2026 Announced Generating Revenue
5. Early Stage VC (Series B2) 04-Jun-2021 Completed Generating Revenue
4. Early Stage VC (Series B1) 29-Dec-2020 Completed Generating Revenue
3. Early Stage VC (Series B) 03-Aug-2020 Completed Generating Revenue
2. Early Stage VC (Series A2) 29-May-2020 $5.6M $11.3M Completed Generating Revenue
1. Early Stage VC (Series A1) 16-Aug-2019 $5.65M $5.65M Completed Generating Revenue
To view Exegenesis’s complete valuation and funding history, request access »

Exegenesis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exegenesis Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
CPE Funds Management PE/Buyout Minority
Lake Bleu Capital Hedge Fund Minority
Temasek Holdings Sovereign Wealth Fund Minority
Hillhouse Investment Group PE/Buyout Minority
LYFE Capital PE/Buyout Minority
You’re viewing 5 of 11 investors. Get the full list »

Exegenesis FAQs

  • When was Exegenesis founded?

    Exegenesis was founded in 2019.

  • Where is Exegenesis headquartered?

    Exegenesis is headquartered in Hangzhou, China.

  • What is the size of Exegenesis?

    Exegenesis has 65 total employees.

  • What industry is Exegenesis in?

    Exegenesis’s primary industry is Drug Discovery.

  • Is Exegenesis a private or public company?

    Exegenesis is a Private company.

  • What is Exegenesis’s current revenue?

    The current revenue for Exegenesis is .

  • How much funding has Exegenesis raised over time?

    Exegenesis has raised $134M.

  • Who are Exegenesis’s investors?

    CPE Funds Management, Lake Bleu Capital, Temasek Holdings, Hillhouse Investment Group, and LYFE Capital are 5 of 11 investors who have invested in Exegenesis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process